|
Atherothrombosis
|
0.050 |
Biomarker
|
disease |
BEFREE |
<i>Preventive and acute treatment of atherothrombosis and arterial embolism; novel ways and tailoring?</i> The role of protease-activated receptor (PAR)-4 vis à vis PAR-1 as target for antithrombotic therapy merits study; ongoing trials on platelet function test-based antiplatelet therapy adjustment support development of practically feasible tests; risk scores for patients with atrial fibrillation need refinement, taking new biomarkers including coagulation into account; risk scores that consider organ system differences in bleeding may have added value; all forms of oral anticoagulant treatment require better organization, including education and emergency access; laboratory testing still needs rapidly available sensitive tests with short turnaround time.5.
|
29378352 |
2018 |
|
Atrial Fibrillation
|
0.050 |
Biomarker
|
disease |
BEFREE |
<i>Preventive and acute treatment of atherothrombosis and arterial embolism; novel ways and tailoring?</i> The role of protease-activated receptor (PAR)-4 vis à vis PAR-1 as target for antithrombotic therapy merits study; ongoing trials on platelet function test-based antiplatelet therapy adjustment support development of practically feasible tests; risk scores for patients with atrial fibrillation need refinement, taking new biomarkers including coagulation into account; risk scores that consider organ system differences in bleeding may have added value; all forms of oral anticoagulant treatment require better organization, including education and emergency access; laboratory testing still needs rapidly available sensitive tests with short turnaround time.5.
|
29378352 |
2018 |
|
Sepsis
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
14-3-3b, CD25, and pP38 protein expression were decreased (P = 0.014, P = 0.004, and P = 0.007, respectively), whereas pAkt expression was induced (P = 0.032).The observed decline of endogenous caveolin-1 protein expression during sepsis implies its involvement in host's cytoprotective reaction either directly, by controlling caveolae population to decrease bacterial burden, or indirectly via regulating 14-3-3b-dependent apoptosis and EPCR-PAR-1-dependent protective signaling.
|
28957875 |
2018 |
|
Septicemia
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
14-3-3b, CD25, and pP38 protein expression were decreased (P = 0.014, P = 0.004, and P = 0.007, respectively), whereas pAkt expression was induced (P = 0.032).The observed decline of endogenous caveolin-1 protein expression during sepsis implies its involvement in host's cytoprotective reaction either directly, by controlling caveolae population to decrease bacterial burden, or indirectly via regulating 14-3-3b-dependent apoptosis and EPCR-PAR-1-dependent protective signaling.
|
28957875 |
2018 |
|
Cholangiocarcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Cholangiocarcinoma and carcinomas from most other sites are negative for Hep Par 1.
|
12645337 |
2003 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Tumor tissue showed increased mRNA levels for PAR-1 but not PAR-2.
|
19424642 |
2009 |
|
Thrombophilia
|
0.020 |
Biomarker
|
disease |
BEFREE |
Hypercoagulable effects are mainly exerted through PAR1 and PAR4, whereas proinflammatory responses are mostly seen after PAR1 and PAR2 activation.
|
29851288 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
PAR-1 and PAR-2 in the cells forming the tumor microenvironment suggest that these receptors mediate the signaling of secreted thrombin and trypsin in the processes of cellular metastasis.
|
11395381 |
2001 |
|
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
PAR-1 and PAR-2 in the cells forming the tumor microenvironment suggest that these receptors mediate the signaling of secreted thrombin and trypsin in the processes of cellular metastasis.
|
11395381 |
2001 |
|
Chronic rejection of renal transplant
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Protease-activated receptor 1 and plasminogen activator inhibitor 1 expression in chronic allograft nephropathy: the role of coagulation and fibrinolysis in renal graft fibrosis.
|
11685117 |
2001 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
PAR-1 plays an important role in the progression of different solid tumours in vitro.
|
11964083 |
2002 |
|
Secondary malignant neoplasm of bone
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
PAR1 expression in a panel of prostate cancer cell lines demonstrated increased expression in those cell lines derived from bone metastases.
|
12429291 |
2002 |
|
Chronic Obstructive Airway Disease
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
PAR-1 protein overexpression in AMs from smokers might be important in the pathophysiology of chronic airways disease.
|
12589358 |
2003 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
PAR1 expression correlates with the invasion properties of breast carcinoma, whereas human PAR1 antisense reduces their ability to migrate through Matrigel.
|
12637343 |
2003 |
|
Coronary Arteriosclerosis
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
PAR-1 genotype influences platelet aggregation and procoagulant responses in patients with coronary artery disease prior to and during clopidogrel therapy.
|
16194864 |
2005 |
|
Coronary Artery Disease
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
PAR-1 genotype influences platelet aggregation and procoagulant responses in patients with coronary artery disease prior to and during clopidogrel therapy.
|
16194864 |
2005 |
|
Coronary heart disease
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
PAR-1 genotype influences platelet aggregation and procoagulant responses in patients with coronary artery disease prior to and during clopidogrel therapy.
|
16194864 |
2005 |
|
Benign Prostatic Hyperplasia
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
PAR1 expression and localization was evaluated using immunohistochemical staining of prostate specimens with benign prostatic hyperplasia (n=27), early- (n=32) and advanced-stage (n=22) prostate cancer.
|
16245281 |
2006 |
|
stage, prostate cancer
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
PAR1 RNA expression in advanced-stage prostate was 2.39-fold higher (P=0.024) and its protein expression was 2.75-fold higher (P=5.89x10(-5)) when compared with early-stage prostate cancer.
|
16245281 |
2006 |
|
Prostatic Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
PAR1 expression was localized to endothelial cells in vascular network of prostate tumor areas.
|
16245281 |
2006 |
|
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
PAR1 has been implicated in tumor cell growth, migration, and invasion whereas the function of PAR2 in these processes is largely unknown.
|
16397244 |
2006 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Protease-activated receptor 1 (PAR1) is emerging with distinct assignments in tumor biology.
|
16707447 |
2006 |
|
Malignant neoplasm of endometrium
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
PAR1 over-expression is selectively confined to the highly aggressive, high-grade endometrial carcinoma and absent in tissue obtained from benign endometrium or low-grade endometrial cancer.
|
16875721 |
2006 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Proteinase-activated receptor-1 (PAR(1)), a thrombin receptor and the prototype of a newly discovered G-protein-coupled receptor subfamily, plays an important role in tumor development and progression.
|
17323377 |
2007 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
LHGDN |
PAR(1)- and PAR(4)-triggered HCC cell migration was blocked by inhibiting a number of key mediators of signal transduction, including G proteins of the G(i)/G(o) family, matrix metalloproteinases, ERK/MAPKinase, cyclic AMP-dependent protein kinase, Src tyrosine kinase, and the EGF receptor kinase.
|
17323377 |
2007 |